Impax Laboratories Inc to Post Q2 2018 Earnings of $0.26 Per Share, Piper Jaffray Forecasts (IPXL)

Impax Laboratories Inc (NASDAQ:IPXL) – Equities researchers at Piper Jaffray issued their Q2 2018 EPS estimates for shares of Impax Laboratories in a research note issued to investors on Monday, April 16th. Piper Jaffray analyst D. Amsellem forecasts that the specialty pharmaceutical company will post earnings of $0.26 per share for the quarter. Piper Jaffray also issued estimates for Impax Laboratories’ Q3 2018 earnings at $0.29 EPS, Q4 2018 earnings at $0.32 EPS, FY2018 earnings at $1.10 EPS, Q1 2019 earnings at $0.31 EPS, Q2 2019 earnings at $0.35 EPS, Q3 2019 earnings at $0.39 EPS, Q4 2019 earnings at $0.45 EPS, FY2019 earnings at $1.50 EPS and FY2020 earnings at $1.85 EPS.

How to Become a New Pot Stock Millionaire

Impax Laboratories (NASDAQ:IPXL) last issued its quarterly earnings data on Thursday, March 1st. The specialty pharmaceutical company reported $0.11 EPS for the quarter, missing analysts’ consensus estimates of $0.12 by ($0.01). Impax Laboratories had a positive return on equity of 10.42% and a negative net margin of 60.49%. The company had revenue of $182.90 million for the quarter, compared to analyst estimates of $199.13 million. During the same quarter in the previous year, the business earned $0.16 earnings per share. The company’s revenue was down 7.8% on a year-over-year basis.

Other equities research analysts have also issued reports about the stock. BidaskClub lowered shares of Impax Laboratories from a “hold” rating to a “sell” rating in a research note on Friday, February 2nd. ValuEngine lowered shares of Impax Laboratories from a “hold” rating to a “sell” rating in a research note on Monday, April 2nd. Canaccord Genuity set a $19.00 price target on shares of Impax Laboratories and gave the company a “hold” rating in a research note on Thursday, March 1st. Zacks Investment Research upgraded shares of Impax Laboratories from a “hold” rating to a “buy” rating and set a $23.00 price target on the stock in a research note on Friday, March 16th. Finally, Cowen set a $21.00 price target on shares of Impax Laboratories and gave the company a “hold” rating in a research note on Thursday, March 1st. Five investment analysts have rated the stock with a sell rating, eight have given a hold rating and six have given a buy rating to the stock. Impax Laboratories presently has an average rating of “Hold” and an average target price of $21.15.

Shares of IPXL stock opened at $20.20 on Thursday. The company has a current ratio of 1.96, a quick ratio of 1.52 and a debt-to-equity ratio of 4.11. Impax Laboratories has a 1 year low of $12.45 and a 1 year high of $25.70. The firm has a market capitalization of $1,455.27, a price-to-earnings ratio of 31.27, a price-to-earnings-growth ratio of 0.88 and a beta of 1.17.

Institutional investors and hedge funds have recently made changes to their positions in the company. Janus Henderson Group PLC bought a new position in shares of Impax Laboratories in the 3rd quarter valued at about $28,573,000. Nationwide Fund Advisors grew its position in shares of Impax Laboratories by 60.1% in the 3rd quarter. Nationwide Fund Advisors now owns 76,769 shares of the specialty pharmaceutical company’s stock valued at $1,558,000 after acquiring an additional 28,830 shares during the period. Rhumbline Advisers grew its position in shares of Impax Laboratories by 14.0% in the 4th quarter. Rhumbline Advisers now owns 177,081 shares of the specialty pharmaceutical company’s stock valued at $2,948,000 after acquiring an additional 21,775 shares during the period. California Public Employees Retirement System grew its position in shares of Impax Laboratories by 8.9% in the 4th quarter. California Public Employees Retirement System now owns 127,428 shares of the specialty pharmaceutical company’s stock valued at $2,122,000 after acquiring an additional 10,428 shares during the period. Finally, TCW Group Inc. grew its position in shares of Impax Laboratories by 3,904.5% in the 4th quarter. TCW Group Inc. now owns 1,987,950 shares of the specialty pharmaceutical company’s stock valued at $33,099,000 after acquiring an additional 1,938,307 shares during the period. 90.40% of the stock is owned by institutional investors.

ILLEGAL ACTIVITY WARNING: This news story was originally posted by The Lincolnian Online and is the sole property of of The Lincolnian Online. If you are reading this news story on another publication, it was illegally stolen and republished in violation of international copyright & trademark legislation. The original version of this news story can be viewed at https://www.thelincolnianonline.com/2018/04/19/impax-laboratories-inc-to-post-q2-2018-earnings-of-0-26-per-share-piper-jaffray-forecasts-ipxl.html.

About Impax Laboratories

Impax Laboratories, Inc is a specialty pharmaceutical company. The Company is engaged in the development, manufacture and marketing of bioequivalent pharmaceutical products (generics), in addition to the development and marketing of branded products. Its segments include Impax Generics and Impax Specialty Pharma.

Earnings History and Estimates for Impax Laboratories (NASDAQ:IPXL)

Receive News & Ratings for Impax Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Impax Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply